Background {#Sec1}
==========

Polymyalgia rheumatica (PMR) affects men and women above the age of 50 and is recognized as the most common chronic inflammatory, rheumatic disease in this age group \[[@CR1]--[@CR3]\]. Clinically, PMR is associated with prominent muscle complaints, including aching and tender and stiff proximal muscles \[[@CR1]\]. Paraclinically, erythrocyte sedimentation rate (ESR) and blood levels of C-reactive protein (CRP) are markedly elevated \[[@CR1]\]. Furthermore, concentrations of proinflammatory cytokines, including also interleukin (IL) 6 \[[@CR4], [@CR5]\], are elevated systemically as well as locally in muscle tissue \[[@CR5]\]. Yet, the prevailing view is that PMR reflects inflammation in the synovia of bursae, joints and tendon sheaths \[[@CR6]\]. Overall, however, the current understanding of the etiology, pathogenesis and pathophysiology of PMR is modest. Treatment with glucocorticoids (GCs) is rapidly effective \[[@CR7], [@CR8]\], and the majority of patients maintains remission, but many experience at least one GC-related serious adverse event \[[@CR9]\].

The genetics of PMR remain elusive; however, the higher incidence in Caucasians \[[@CR10]\] and the higher susceptibility in people carrying the HLA-DRB1\*04 allele \[[@CR11]\] suggest that genetic factors may in fact impact the pathophysiology of the disease. Studies have found associations between polymorphisms in the genes encoding e.g. IL-6 and tumor necrosis factor alpha (TNF-**α**) and the susceptibility to and severity of PMR \[[@CR12]\], but generally findings have been inconclusive \[[@CR13], [@CR14]\].

In the present study, to extend the understanding of the pathophysiology of PMR, we profiled the gene expression in muscle tissue from GC-naive patients with PMR and matched non-PMR control subjects before and after symptom-eliminating treatment with prednisolone.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Nine GC-naive patients with newly diagnosed, untreated PMR and 10 matched (age, sex, and BMI) non-PMR control subjects were studied in the fasting state in the morning before and after 14 days of prednisolone treatment (20 mg/day taken in the morning, also 1--2 h before the second biopsy) in a comprehensive clinical experimental research program, some of the results of which we recently reported \[[@CR5], [@CR15]\]. The study was approved by the Ethical Committee of Copenhagen (approval number: KF\[01\]261665) and informed consent was obtained before study inclusion. Anthropometric data are given in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of the PMR patients and the non-PMR control subjectsPMR patients\
(*n* = 9)Controls\
(*n* = 10)Female/male5/45/5Age, mean (range), years74.2 (60.5--87.2)72.3 (63.4--85.2)Body--mass index, mean (range), kg/m^2^24.3 (16.5--28.7)25.7 (22.1--29.3)ESR, mean (range) mm/h Before treatment66 (43--74) ^†^9 (3--11) After treatment13 (4--23) ^‡^7 (4--10)CRP, mean (range) mg/l Before treatment55 (27--131)^†^2 (0--10) After treatment5 (0--11)^‡^2 (1--8)^†^ *p* \< 0.05 vs. control subjects. ^‡^ *p* \< 0.05 vs. untreated patients

Patients were diagnosed with PMR according to the criteria proposed by Chuang and colleagues \[[@CR2], [@CR3], [@CR16], [@CR17]\], and the diagnosis was later supported by normalization of ESR and CRP upon prednisolone treatment. Patients were recruited by referral from general practitioners; control subjects were recruited by newspaper advertising and included in the study after a standard medical examination and a comprehensive blood and urine screening. Both groups did not meet the exclusion criteria described by Kreiner and colleagues \[[@CR5]\]. Controlled chronic comorbidities were accepted in both groups. Diminishing the possibility of occult malignant disease, all subjects had normal thorax X-ray and abdominal ultrasound examination, and negative test for blood in the stools and urine. In addition, all subjects had comprehensive blood screening performed. In patients, only ESR and CRP were different from normal values; no blood values in control subjects were abnormal.

Some subjects received concurrent medication as previously detailed \[[@CR5]\]. Before the first experiment, non-steroidal anti-inflammatory drug treatment was not allowed, and use of analgesics was limited to the centrally-acting opioid-like drug tramadol (Mandolgin, Mandoz A/S, Odense, Denmark); none of the subjects had taken tramadol in the morning before any of the two experiments.

Experiments and interventions {#Sec4}
-----------------------------

From all subjects, biopsies were obtained from trapezius muscles before and after treatment with prednisolone; in all patients, the trapezius muscle exhibited the symptoms characteristic of PMR, i.e. aching, tenderness and stiffness. Following local anesthesia of the skin and subcutis with Lidocaine (20 mg/mL), muscle tissue was sampled through a small incision in the cutis, subcutis and muscle fascia using a 5 mm Bergström needle with suction \[[@CR18]\]. Muscle samples were snap-frozen in liquid nitrogen, weighed (wet weight ranged from 35 to 100 mg per sample), and stored at −80 °C until RNA extraction.

Total RNA extraction {#Sec5}
--------------------

Total RNA was extracted from 20 to 30 mg muscle sample by tissue homogenization in TriReagent (Molecular Research Center, Cincinnati, Ohio, US) using a bead-mixer (FastPrep®-24 instrument, MP Biomedicals, Illkirch, France) with five inert 2.3 mm steel beads (BioSpec Products, Bartlesville, OK, US) and one siliciumcarbid crystal followed by addition of bromo-chloropropane to separate the homogenate into aqueous and organic phases. To precipitate RNA, isopropanol was added to the isolated aqueous phase. The precipitated total RNA was washed repeatedly in 75% ethanol and dissolved in RNAse-free water before storing at −80 °C until further analysis. Total RNA concentrations were determined by spectroscopy; yields averaged 0.4 μg total RNA/mg muscle tissue.

DNA microarray analysis {#Sec6}
-----------------------

### Sample preparation and hybridization, and detection and quantification of signals {#Sec7}

Total RNA was further purified using RNeasy Mini Kits (Qiagen, Valencia, CA, US), and the integrity and purity of the RNA was verified using an Agilent Bioanalyser (Agilent, Palo Alto, CA, US) as previously described \[[@CR19]\]. Based on the quality of the RNA, 8 patient samples and 10 control subject samples were selected for microarray assessment. ds-cDNA was synthesized from 2 μg total RNA using an oligo-dT primer containing a T7 RNA polymerase promoter, and labeled in an T7 promoter-driven in vitro transcription reaction producing biotin-labeled cRNA from the cDNA according to the manufacturer's (Affymetrix, Santa Clara, CA, US) guidelines. Next, the hybridization mixture was prepared from the fragmented target cRNA as well as probe array controls, bovine serum albumin, and herring sperm DNA.

Affymetrix GeneChip Human Genome U133 Plus 2.0 (Santa Clara, CA, US) arrays, which comprise 54,675 probe sets, were used. Following hybridization, the probe arrays were washed and stained with phycoerytrin streptavidin (SAPE) using the Affymetrix Fluidics Station 450 and scanned using an Affymetrix GeneArray 3000 7G scanner 488 nm to generate fluoresecent images as described in the Affymetrix GeneChip protocol. The amount of bound target at each location of the probe array is proportional to the amount of bound light emitted at 570 nm. Scanned data were stored as image files in cel-format.

### Data analysis {#Sec8}

Cel-files were imported into the statistical software package R v. 2.7.2 using BioConductor v. 2.8 \[[@CR20]\], and gcRMA modeled using quantiles normalization and median polish summarization \[[@CR21]\]. The modeled log-intensity of approximately 54,600 probe sets was used for selecting differentially expressed genes. The microarray data were submitted to the gene expression repository at Array Express ([http://www.ebi.ac.uk/arrayexpress/](http://www.ebi.ac.uk/arrayexpress)) with accession number E-MTAB-3671. Differentially expressed genes were selected based on an initial two-way ANOVA analysis including the parameters disease (PMR versus control) and treatment (before versus after treatment) with a *p*-value \<0.05 and mutual fold change cut-off of 1.2 and reflecting either main effect or intervention. The resulting 565 selected probe sets were further analyzed. Pairwise differentially expressed transcripts were depicted by a univariate two-sample t-test with equal variance. Multiple testing corrections were performed using the multtest package in Bioconducter v. 2.7.2. Control of Type I error rate was performed by computing adjusted *p*-values for simple multiple testing procedures from a vector of raw (unadjusted) *p*-values by applying the Benjamini & Hochberg FDR analysis \[[@CR22]\]. Only transcripts exhibiting a fold change larger than 1.2 and a difference of means larger than 30 (real unlogged values) between (mutual) classes were considered.

### Gene grouping criteria {#Sec9}

Predefined criteria were applied to identify genes of potential pathophysiological impact. The criteria were: 1. difference in expression level between untreated patients and untreated controls (Table [2](#Tab2){ref-type="table"}), and 2. response to prednisolone treatment of expression levels in a given direction in patients only (Table [3](#Tab3){ref-type="table"}). Those genes that differed between untreated patients and controls and that also responded to prednisolone treatment in patients, i.e. the aggregate of criteria 1 and 2, were also identified (criterion 3) (Table [4](#Tab4){ref-type="table"}).Table 2Genes the expression levels of which differed between untreated patients and untreated controls (78 genes)Gene symbolGene nameProbe set(s)FD^a^pBDNFbrain-derived neurotrophic factor244503_at+1.80.016ETS2v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)201328_at+1.80.007SVIPsmall VCP/p97-interacting protein230285_at+1.70.002SH3RF2SH3 domain containing ring finger 2228892_at+1.60.004TM4SF18transmembrane 4 L six family member 18230061_at+1.50.007TMTC1transmembrane and tetratricopeptide repeat containing 1226322_at\
226931_at+1.5\
+1.60.003\
\<0.001TMEM18transmembrane protein 18225489_at+1.50.008N4BP2L1NEDD4 binding protein 2-like 1213375_s\_at+1.50.019FMO2flavin containing monooxygenase 2 (non-functional)228268_at+1.50.002RPL37ribosomal protein L37224763_at+1.5\<0.001CTDSP2CTD (carboxy-terminal domain. RNA polymerase II. polypeptide A) small phosphatase 2238999_at+1.40.048RASL10BRAS-like. Family 10. member B235488_at+1.40.012SMG1P1nuclear pore complex interacting protein-like231989_s\_at+1.40.008ZNF331zinc finger protein 331219228_at+1.4\<0.001FAM184Bfamily with sequence similarity 184. member B235288_at+1.40.013LOC100507303uncharacterized LOC100507303228049_x\_at+1.40.019NCKIPSDNCK interacting protein with SH3 domain218697_at+1.4\<0.001ECHDC3enoyl CoA hydratase domain containing 3219298_at+1.30.049RNF114ring finger protein 114200867_at\
200868_s\_at\
211678_s\_at+1.3\
+1.3\
+1.20.006\
0.023\
0.018TMPOthymopoietin224944_at+1.30.002REREarginine-glutamic acid dipeptide (RE) repeats200940_s\_at+1.30.003TUBD1tubulin. Delta 1231853_at+1.30.003MARK4MAP/microtubule affinity-regulating kinase 455065_at+1.30.005ZNF195zinc finger protein 195204234_s\_at+1.30.003PCF11PCF11. cleavage and polyadenylation factor subunit. Homolog (*S. cerevisiae*)203378_at+1.30.007DFFADNA fragmentation factor. 45 kDa. alpha polypeptide226116_at+1.30.010PSPC1paraspeckle component 1218371_s\_at+1.30.007RBBP6retinoblastoma binding protein 6212783_at+1.30.004EIF4Beukaryotic translation initiation factor 4B211937_at+1.30.017NPM1nucleophosmin (nucleolar phosphoprotein B23. numatrin)221691_x\_at+1.30.011RSBN1round spermatid basic protein 1213694_at+1.20.003PSIP1PC4 and SFRS1 interacting protein 1209337_at+1.20.010EIF3Geukaryotic translation initiation factor 3. subunit G208887_at+1.20.006COL4A3BPcollagen. Type IV. alpha 3 (Goodpasture antigen) binding protein219625_s\_at\
223465_at+1.2\
+1.20.003\
0.029PCID2PCI domain containing 2219940_s\_at+1.20.003PXDC1PX domain containing 1212923_s\_at+1.20.042BCKDHAbranched chain keto acid dehydrogenase E1, alpha polypeptide202331_at+1.20.024AKR7A2aldo-keto reductase family 7, member A2202139_at+1.20.010MRPS2mitochondrial ribosomal protein S2218001_at+1.20.018RORARAR-related orphan receptor A226682_at+1.20.049RPL36ALribosomal protein L36a-like207585_s\_at+1.20.011TFRCtransferrin receptor (p90, CD71)208691_at--3.00.004SFRP4secreted frizzled-related protein 4204051_s\_at\
204052_s\_at−2.90.001\
0.002NOVnephroblastoma overexpressed214321_at−2.00.037PAQR9progestin and adipoQ receptor family member IX1558322_a\_at−2.0\<0.001C2orf88chromosome 2 open reading frame 88228195_at−1.90.011FAM69Afamily with sequence similarity 69, member A213689_x\_at−1.80.001TP53INP2tumor protein p53 inducible nuclear protein 2224836_at−1.8\
−1.9\<0.001\
0.002SH3KBP1SH3-domain kinase binding protein 11554168_a\_at\
223082_at−1.80.002NINJ2ninjurin 2219594_at−1.70.039MESTmesoderm specific transcript homolog (mouse)202016_at−1.70.010ITGB1BP2integrin beta 1 binding protein (melusin) 2219829_at−1.6\<0.001PLXDC1plexin domain containing 1219700_at−1.50.006BPGM2,3-bisphosphoglycerate mutase203502_at−1.5\<0.001MTFP1mitochondrial fission process 1223172_s\_at−1.50.004MAP2K3mitogen-activated protein kinase kinase 3215499_at−1.50.003LRRN4CLLRRN4 C-terminal like1556427_s\_at−1.40.042FBXO9F-box protein 9210638_s\_at212987_at−1.4\
−1.4\<0.001\
\<0.001HERC1HECT and RLD domain containing E3 ubiquitin protein ligase family member 1218306_s\_at−1.4\<0.001JARID2jumonji, AT rich interactive domain 2203297_s\_at−1.4\<0.001TRAK1trafficking protein, kinesin binding 1202079_s\_at−1.40.004ZNF252Pzinc finger protein 252, pseudogene228200_at−1.4\<0.001PRSS23protease, serine, 23202458_at−1.40.030OLFML2Bolfactomedin-like 2B213125_at−1.40.049MSANTD4Myb/SANT-like DNA-binding domain containing 4 with coiled-coils227418_at−1.30.043ZDHHC7zinc finger, DHHC-type containing 7218606_at−1.3\<0.001RAP2ARAP2A, member of RAS oncogene family225585_at−1.30.016LRP12low density lipoprotein receptor-related protein 12219631_at−1.30.050BMPR1Abone morphogenetic protein receptor, type IA213578_at−1.30.001RNF10ring finger protein 10207801_s\_at−1.3\<0.001COL5A1collagen, type V, alpha 1203325_s\_at−1.30.007INSIG1insulin induced gene 1201626_at−1.30.046SLC35E3solute carrier family 35, member E3218988_at−1.30.003MEMO1dpy-30 homolog (*C. elegans*) /// mediator of cell motility 1219065_s\_at−1.30.004MYL4myosin, light chain 4, alkali; atrial, embryonic210395_x\_at−1.20.002COX7A2cytochrome c oxidase subunit VIIa polypeptide 2 (liver)201597_at−1.20.019MGAT4Bmannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B224598_at−1.20.003MRC2mannose receptor, C type 2209280_at−1.20.010*FD* fold difference. ^a^ fold differences for genes with more than one probe set were calculated as the average of the individual values, which did not differ markedly Table 3Genes the expression levels of which responded to prednisolone treatment in a given direction only in patients with polymyalgia rheumatica (131 genes)Gene symbolGene nameProbe set(s)FC^a^pCOL1A1collagen, type I, alpha 11556499_s\_at+4.70.028CTGFconnective tissue growth factor209101_at+2.90.012MESTmesoderm specific transcript homolog (mouse)202016_at+2.70.049CDH11cadherin 11, type 2, OB-cadherin (osteoblast)207173_x\_at+2.60.012S1PR3sphingosine-1-phosphate receptor 3228176_at+2.50.009CD248CD248 molecule, endosialin219025_at+2.50.019FBN1fibrillin 1202766_s\_at\
235318_at+2.4\
+2.10.031\
0.017NINJ2ninjurin 2219594_at+2.30.002MFAP5microfibrillar associated protein 5209758_s\_at\
213764_s\_at\
213765_at+2.7\
+2.2\
+2.10.038\
0.010\
0.018SH3PXD2BSH3 and PX domains 2B231823_s\_at+2.20.011C13orf33chromosome 13 open reading frame 33227058_at+2.20.044FOSL2FOS-like antigen 2218880_at+2.20.026BGNbiglycan201261_x\_at+2.10.029NEDD9neural precursor cell expressed, developmentally down-regulated 9233223_at+2.10.004COL5A2collagen, type V, alpha 2221730_at+2.00.049NT5E5′-nucleotidase, ecto (CD73)203939_at+2.00.044TUBB6tubulin, beta 6 class V209191_at+2.00.031SPARCsecreted protein, acidic, cysteine-rich (osteonectin)200665_s\_at+2.00.043FN1fibronectin 1210495_x\_at\
211719_x\_at\
212464_s\_at\
216442_x\_at+1.9\
+1.9\
+1.9\
+2.00.045\
0.042\
0.046\
0.038GFPT2glutamine-fructose-6-phosphate transaminase 2205100_at+1.90.034NFKBIZnuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta223217_s\_at+1.90.025DCLK1doublecortin-like kinase 1205399_at+1.90.034METRNLmeteorin, glial cell differentiation regulator-like225955_at+1.90.023COL1A2collagen, type I, alpha 2229218_at+1.80.048LAMB1laminin, beta 1201505_at+1.80.003LSP1P1lymphocyte-specific protein 1 pseudogene214110_s\_at+1.80.020COL6A3collagen, type VI, alpha 3201438_at+1.80.003GAS7growth arrest-specific 7202191_s\_at\
202192_s\_at+1.8\
+1.70.028\
0.021ARHGAP26Rho GTPase activating protein 26244548_at+1.80.003OLFML2Bolfactomedin-like 2B213125_at+1.70.031SPON2spondin 2, extracellular matrix protein218638_s\_at+1.70.002COL6A1collagen, type VI, alpha 1213428_s\_at+1.70.006CILPcartilage intermediate layer protein, nucleotide pyrophosphohydrolase206227_at+1.70.012OLFML3olfactomedin-like 3218162_at+1.70.026FAM69Afamily with sequence similarity 69, member A213689_x\_at+1.7\<0.001CORO1Ccoronin, actin binding protein, 1C222409_at+1.60.020MAP1Bmicrotubule-associated protein 1B226084_at+1.60.039COL6A2collagen, type VI, alpha 2209156_s\_at+1.60.020PRKCDBPprotein kinase C, delta binding protein213010_at+1.6\<0.001CLIC4chloride intracellular channel 4201560_at+1.60.010LRRN4CLLRRN4 C-terminal like1556427_s\_at+1.50.006CD109CD109 molecule226545_at+1.50.034DBN1drebrin 1202806_at+1.50.020SFXN3sideroflexin 3220974_x\_at+1.50.016TNXA / TNXB**tenascin XA (pseudogene) / tenascin XB206093_x\_at**\
**213451_x\_at**\
**216333_x\_at+1.5**\
**+1.5**\
**+1.50.030**\
**0.034**\
**0.041**PRSS23protease, serine, 23202458_at+1.50.022TUBA1Atubulin, alpha 1a209118_s\_at+1.50.038SAMHD1SAM domain and HD domain 1235529_x\_at+1.50.024ITGB1BP2integrin beta 1 binding protein (melusin) 2219829_at+1.50.003ATP2C1ATPase, Ca++ transporting, type 2C, member 1209934_s\_at+1.5\<0.001PXDC1PX domain containing 1212923_s\_at+1.50.014PAQR9progestin and adipoQ receptor family member IX1558322_a\_at+1.40.027P4HA2prolyl 4-hydroxylase, alpha polypeptide II202733_at+1.40.024ANXA2annexin A2201590_x\_at\
210427_x\_at\
213503_x\_at+1.4\
+1.4\
+1.40.025\
0.027\
0.032ACVRL1activin A receptor type II-like 1226950_at+1.40.009CHSY1chondroitin sulfate synthase 1203044_at+1.40.021C10orf54chromosome 10 open reading frame 54225373_at+1.40.016PLAGL1pleiomorphic adenoma gene-like 1207943_x\_at+1.40.012CTTNBP2NLCTTNBP2 N-terminal like226000_at+1.40.019SYNPO2synaptopodin 2225720_at+1.40.013ANXA2P2annexin A2 pseudogene 2208816_x\_at+1.40.042TGFB1I1transforming growth factor beta 1 induced transcript 1209651_at+1.40.043ACTBactin, beta213867_x\_at\
224594_x\_at\
200801_x\_at+1.4\
+1.4\
+1.40.048\
0.040\
0.033TRIOtriple functional domain (PTPRF interacting)208178_x\_at\
209012_at+1.40.018ITGA5integrin, alpha 5 (fibronectin receptor, alpha polypeptide)201389_at+1.40.038RRBP1ribosome binding protein 1 homolog 180 kDa (dog)201204_s\_at+1.40.010LASP1LIM and SH3 protein 1200618_at+1.40.016ADNP2ADNP homeobox 2203321_s\_at+1.30.009MTFP1mitochondrial fission process 1223172_s\_at+1.30.017TP53INP2tumor protein p53 inducible nuclear protein 2224836_at+1.30.017PDGFRBplatelet-derived growth factor receptor, beta polypeptide202273_at+1.30.009FBXO9F-box protein 9210638_s\_at\
212987_at+1.3\
+1.30.002\
\<0.001VAT1vesicle amine transport protein 1 homolog (*T. californica*)208626_s\_at+1.30.043LTBP1latent transforming growth factor beta binding protein 1202729_s\_at+1.30.026HIF1Ahypoxia inducible factor 1, alpha subunit200989_at+1.30.025SH3KBP1SH3-domain kinase binding protein 11554168_a\_at\
223082_at+1.3\
+1.30.044\
0.027JARID2jumonji, AT rich interactive domain 2203297_s\_at+1.30.007ACTG1actin, gamma 1201550_x\_at\
211970_x\_at\
211983_x\_at\
211995_x\_at\
212363_x\_at\
212988_x\_at\
213214_x\_at+1.3\
+1.3\
+1.3\
+1.3\
+1.3\
+1.3\
+1.30.015\
0.009\
0.031\
0.013\
0.020\
0.017\
0.021MAP2K3mitogen-activated protein kinase kinase 3215499_at+1.30.021MEMO1mediator of cell motility 1219065_s\_at+1.30.012EZRezrin208623_s\_at+1.30.002BPGM2,3-bisphosphoglycerate mutase203502_at+1.20.036TUBBtubulin, beta class I212320_at+1.20.039DDAH1dimethylarginine dimethylaminohydrolase 1209094_at+1.20.033BDNFbrain-derived neurotrophic factor244503_at−3.10.001SLC25A34solute carrier family 25, member 341559977_a\_at\
232245_at−1.9\
−1.90.006\
0.009SVIPsmall VCP/p97-interacting protein230285_at−1.70.004VPS8vacuolar protein sorting 8 homolog (S. cerevisiae)239917_at−1.6\<0.001PIAS2protein inhibitor of activated STAT, 2244633_at−1.60.011LOC100507303uncharacterized LOC100507303228049_x\_at−1.60.004RPL37ribosomal protein L37224763_at−1.5\<0.001TMTC1transmembrane and tetratricopeptide repeat containing 1226322_at\
226931_at−1.4\
−1.60.005\
\<0.001MLYCDmalonyl-CoA decarboxylase218869_at−1.50.004UCP3uncoupling protein 3 (mitochondrial, proton carrier)207349_s\_at−1.50.016TUBD1tubulin, delta 1231853_at−1.40.003BCKDHAbranched chain keto acid dehydrogenase E1, alpha polypeptide202331_at−1.40.004TRIM39tripartite motif containing 39222732_at−1.40.002ZNF331zinc finger protein 331219228_at−1.40.003NRBF2nuclear receptor binding factor 2223650_s\_at−1.40.021GTF2H5general transcription factor IIH, polypeptide 5244294_at−1.40.007FMO2flavin containing monooxygenase 2 (non-functional)228268_at−1.40.002TMEM18transmembrane protein 18225489_at−1.40.028HSDL2Hydroxysteroid dehydrogenase like 2215436_at−1.40.006N4BP2L1NEDD4 binding protein 2-like 1213375_s\_at−1.40.033PEBP4phosphatidylethanolamine-binding protein 4227848_at−1.40.009RANBP9RAN binding protein 9216125_s\_at−1.40.002ST3GAL5ST3 beta-galactoside alpha-2,3-sialyltransferase 5203217_s\_at−1.30.003ACADSBacyl-CoA dehydrogenase, short/branched chain226030_at−1.30.006RNF114ring finger protein 114200867_at\
200868_s\_at\
211678_s\_at−1.3\
−1.3\
−1.20.020\
0.030\
0.041MRPS2mitochondrial ribosomal protein S2218001_at−1.30.006TMEM50Btransmembrane protein 50B219600_s\_at−1.30.027EIF3Geukaryotic translation initiation factor 3, subunit G208887_at−1.30.005PSIP1PC4 and SFRS1 interacting protein 1209337_at−1.30.007PTP4A1protein tyrosine phosphatase type IVA, member 1200732_s\_at−1.3\<0.001EIF4Beukaryotic translation initiation factor 4B211937_at−1.30.015FAM184Bfamily with sequence similarity 184, member B235288_at−1.30.042CNNM3cyclin M3229031_at−1.30.011REREarginine-glutamic acid dipeptide (RE) repeats200940_s\_at−1.30.008ZNF195zinc finger protein 195204234_s\_at−1.30.002SNRPAsmall nuclear ribonucleoprotein polypeptide A201770_at−1.30.025TM4SF18transmembrane 4 L six family member 18230061_at−1.30.033RPL36ALribosomal protein L36a-like207585_s\_at−1.20.008RBBP6retinoblastoma binding protein 6212783_at−1.20.025TSFMTs translation elongation factor, mitochondrial214331_at−1.20.019POLR1Bpolymerase (RNA) I polypeptide B, 128 kDa223403_s\_at−1.20.018NPM1nucleophosmin (nucleolar phosphoprotein B23, numatrin)221691_x\_at−1.20.022OXA1Loxidase (cytochrome c) assembly 1-like208717_at−1.20.027RSBN1round spermatid basic protein 1213694_at−1.20.016AKR7A2aldo-keto reductase family 7, member A2202139_at−1.20.002RORA**RAR-related orphan receptor A226682_at−1.20.044**DFFADNA fragmentation factor, 45 kDa, alpha polypeptide226116_at−1.20.016FC, fold change. Entries in **bold** indicate that genes also responded significantly (but in the opposite direction) in control subjects. Responses in controls for both these genes, TNXA/TNXB and RORA, were of the same magnitude as in patients but in the opposite direction. ^a^fold changes for genes with more than one probe set were calculated as the average of the individual values, which did not differ markedly Table 4Genes the expression levels of which differed between untreated patients with polymyalgia rheumaticaand untreated controls (FD), and which responded to prednisolone treatment in the patients (FC) (44 genes)Gene symbolGene nameFD^a^pFC^b^pBDNFbrain-derived neurotrophic factor+1.80.016−3.10.001SVIPsmall VCP/p97-interacting protein+1.70.002−1.70.004TM4SF18transmembrane 4 L six family member 18+1.50.007−1.30.033TMTC1transmembrane and tetratricopeptide repeat containing 1+1.50.001−1.50.003TMEM18transmembrane protein 18+1.50.008−1.40.028N4BP2L1NEDD4 binding protein 2-like 1+1.50.019−1.40.033FMO2flavin containing monooxygenase 2 (non-functional)+1.50.002−1.40.012RPL37ribosomal protein L37+1.5\<0.001−1.5\<0.001FAM184Bfamily with sequence similarity 184, member B+1.40.013−1.30.042LOC100507303uncharacterized LOC100507303+1.40.019−1.60.004RNF114ring finger protein 114+1.30.016−1.30.030REREarginine-glutamic acid dipeptide (RE) repeats+1.30.003−1.30.008TUBD1tubulin, delta 1+1.30.003−1.40.003ZNF195zinc finger protein 195+1.30.003−1.30.002DFFADNA fragmentation factor, 45 kDa, alpha polypeptide+1.30.010−1.20.016RBBP6retinoblastoma binding protein 6+1.30.004−1.20.025NPM1nucleophosmin (nucleolar phosphoprotein B23, numatrin)+1.30.011−1.20.022EIF4Beukaryotic translation initiation factor 4B+1.30.017−1.30.015RSBN1round spermatid basic protein 1+1.20.003−1.20.016PSIP1PC4 and SFRS1 interacting protein 1+1.20.010−1.30.007EIF3Geukaryotic translation initiation factor 3, subunit G+1.20.006−1.30.005PXDC1PX domain containing 1+1.20.042+1.50.014BCKDHAbranched chain keto acid dehydrogenase E1, alpha polypeptide+1.20.024−1.40.004AKR7A2aldo-keto reductase family 7, member A2+1.20.010−1.20.002MRPS2mitochondrial ribosomal protein S2+1.20.018−1.30.006RORA**RAR-related orphan receptor A+1.20.049−1.20.044**RPL36ALribosomal protein L36a-like+1.20.011−1.20.008PAQR9progestin and adipoQ receptor family member IX−2.0\<0.001+1.40.027FAM69Afamily with sequence similarity 69, member A−1.80.001+1.7\<0.001TP53INP2tumor protein p53 inducible nuclear protein 2−1.8\<0.001+1.30.017SH3KBP1SH3-domain kinase binding protein 1−1.80.002+1.30.035NINJ2ninjurin 2−1.70.039+2.30.002MESTmesoderm specific transcript homolog (mouse)−1.70.010+2.70.049ITGB1BP2integrin beta 1 binding protein (melusin) 2−1.6\<0.001+1.50.003BPGM2,3-bisphosphoglycerate mutase−1.5\<0.001+1.20.036MTFP1mitochondrial fission process 1−1.50.004+1.30.017MAP2K3mitogen-activated protein kinase kinase 3−1.50.003+1.30.021LRRN4CLLRRN4 C-terminal like−1.40.042+1.50.006FBXO9F-box protein 9−1.4\<0.001+1.30.001JARID2jumonji, AT rich interactive domain 2−1.4\<0.001+1.30.007PRSS23protease, serine, 23−1.40.030+1.50.022OLFML2Bolfactomedin-like 2B−1.40.049+1.70.031MEMO1mediator of cell motility 1−1.30.004+1.30.012*FD* fold difference, *FC* fold change^a^ + and −; expression levels were higher and lower, respectively, in patients with polymyalgia rheumatica than in controls before treatment with prednisolone^b^ + and −; expression levels increased and decreased, respectively, in patients with polymyalgia rheumatica after treatment with prednisoloneEntry in **bold** indicates that the gene also responded significantly to prednisolone in controls. The response in controls for the RORA gene was of the same magnitude as in patients but in the opposite direction

### Assessment of biological function {#Sec10}

For genes in all three criteria sets, biological functions were assessed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool \[[@CR23]\] with default options and annotations current as of February 2013. Functional annotation clustering was performed; this process associates individual genes in a large gene list with biological terms and group sets of genes according to functionally similar terms. Moreover, the importance of each cluster is ranked using enrichment scores, which are the geometric means of the enrichment *P* values (EASE score \[[@CR24]\]) for each annotation term in the cluster. While enrichment scores above 1.3 are considered particularly interesting, clusters with scores below 1.3 could also be of central importance (e.g. short gene lists do not generally get very high enrichment scores, illustrating that categories with lower scores may still be biologically relevant) \[[@CR23]\]. In the presentation of the results, clusters with the highest enrichment scores will be presented.

Quantitative RT-PCR {#Sec11}
-------------------

To confirm mRNA level fold differences and fold changes found using the microarrays, mRNA levels for a selection (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}) of the filtered genes were measured using quantitative real-time PCR (qRT-PCR). Moreover, mRNA levels for additional genes (Table [5](#Tab5){ref-type="table"}) that did not differ using microarrays, but which were of particular interest in elucidating the PMR disease mechanisms, were included in the qRT-PCR analysis.Table 5Quantitative RT-PCR fold differences between untreated patients with polymyalgia rheumatica (PMR) and non-PMR controls, and fold changes between treated and untreated PMR patientsGene symbolFold differences^b^Fold changes^c^(probe name)qRT-PCRMicroarray^a^qRT-PCRMicroarray^**a**^*Genes that differed in microarray testing in at least one comparison*BDNF+1.90\*+1.80 \*−1.58 \*\*−3.1 \*\*COL5A1−1.33 ns−1.30 \*\*+1.73 ns+2.30 nsEIF4B+1.63 *p* = 0.0504+1.30 \*−1.23 \*−1.30 \*MARK4+1.32 ns+1.30 \*\*−1.24 \*−1.15 nsMTFP1+1.00 ns−1.50 \*\*+1.33 \*+1.30 \*NPM1+1.38 \*\*+1.30 \*−1.09 ns−1.22 \*PRSS23−1.21 ns−1.40 \*+1.27 ns+1.51 \*TFRC−1.63 ns−3.00 \*+1.17 ns+1.76 nsTUBD1+1.26 \*\*+1.30 \*\*−1.08 ns−1.40 \*\**Genes that did not differ in microarray testing*ACTA1\
(203872_at)−1.03 ns−1.02 ns1.06 ns+1.00 nsDES^a^\
(216947_at\
202222_s\_at\
214027_x\_at)+1.16 ns+1.00 ns−1.07 ns+1.00 nsIL6\
(205207_at)+4.54 \*+1.02 ns−3.25 \*+1.02 nsTNFA\
(207113_s\_at)+1.31 ns+1.00 ns−1.31 ns−1.00 nsTUBA8\
(220069_at)−1.02 ns−1.02 ns+1.10 ns+1.00 ns*qRT-PCR* quantitative real-time PCR^\*^ *p* \< 0.05. ^\*\*^ *p* \< 0.01. ns, not statistically significant. Data are geometric means^a^ Microarray numbers were calculated as the mean of the individual probe values^b^ + and −, expression levels were higher and lower, respectively, in patients with polymyalgia rheumatica than in controls before treatment with prednisolone^c^ + and −, expression levels increased and decreased, respectively, in patients with polymyalgia rheumatica after treatment with prednisolone Table 6qRT-PCR primer sequencesGeneSenseAntisenseACTA1GCCGTGTTCCCGTCCATCGTTTCAGGGTCAGGATACCTCTCTTGCTBDNFGAGGGGAGCTGAGCGTGTGTGTTTTTGTCTGCCGCCGTTACCCCOL5A1CGCCGACACCTCCAACTCCTCCTCAGTGAACTCCCCCTCCAADESCCATCCAGACCTACTCTGCCCTCTTGGTATGGACCTCAGAACCCCTTTEIF4BCGTCAGCTGGATGAGCCAAAAGTCCTCGACCGTTCCCGTTCCIL6GAGGCACTGGCAGAAAACAACCCCTCAAACTCCAAAAGACCAGTGATGMARK4AGATCCCAGAGCGGCGGAAGGGGTCATCATGCTAGGAGGGAGGTTMTFP1AAGGCAAGAAGGCTGGAGAGGTGACAGAGGCTAGAGCCTGCCATACAAANPM1GGTTTCCCTTGGGGGCTTTGGCACTGGCCCTGAACCACACTTPRSS23CAGCGGGTCTGGGGTCTATGGCCAATAATTTTTCGCTCCCACTTCTTUBD1TGATTGTTGGGAAGGCATGGACAACAACCTGCTCTAATGACGTGAAATFRCTCGGGAATGCTGAGAAAACAGACATTTTGGAGATACGTAGGGAGAGAGGAATNFATTCCCCAGGGACCTCTCTCTAATCGAGGGTTTGCTACAACATGGGCTACTUBA8GCCCAAGGATGTGAATGTCGCTGGTCGGGGGCTGGTAGTTGATGRPLP0GGAAACTCTGCATTCTCGCTTCCTCCAGGACTCGTTTGTACCCGTTG*qRT-PCR* quantitative real-time PCRThe primer set sequence for BDNF provided in Table [6](#Tab6){ref-type="table"} recognizes all BDNF isoforms; using this primer set, the results presented in Table [5](#Tab5){ref-type="table"} were obtained. The BDNF mRNA levels were also assessed with qRT-PCR using a BDNF primer set that specifically recognizes the BDNF isoform that is recognized by the probe on the used microarray; the results (fold difference + 1.53, *p* \< 0.1; fold change −2.4, *p* \< 0.01) from this additional assessment were very similar to the results presented in Table [5](#Tab5){ref-type="table"}

From 9 patient samples and 9 control subject samples, cDNA was synthesized using Omniscript reverse transcriptase (Qiagen, Hilden, Germany) from 500 ng total RNA (same pool as used in the microarray runs) in 20 μl. For each target mRNA, 0.25 μl cDNA was amplified in 25 μl Quantitect SYBR Green Master Mix (Qiagen) with corresponding primers (100 nM of both antisense and sense primers, Table [6](#Tab6){ref-type="table"}) on a Stratagene MX3000P RT-PCR instrument (Stratagene, La Jolla, CA, US).

The applied thermal profile was as follows: 95°Celsius, 10 min-(95 °C, 15 s-58 °C, 30s-63°C, 90s)×50--95 °C, 60s-55°C, 30s-95°C, 60s. Standard curves were made using dilution series of a cDNA pool and related to the threshold cycles (C~t~) at the 63 °C step at which the signal intensity was acquired. To ensure specificity, melting curves were analyzed post amplification (at the 55 °C to 95 °C step). The C~t~ values for the samples were converted to relative values using the standard curves and normalized to the internal "housekeeping" control, ribosomal protein P0 (RPLP0). Microarray analysis confirmed that the RPLP0 mRNA level is stable under the current conditions and therefore suitable as the normalizer.

Statistics {#Sec12}
----------

Statistical methods used in the evaluation of the microarray data are described above. Data are reported in compliance with the guidelines for minimum information about a microarray experiment (MIAME).

Statistical analyses of qRT-PCR and anthropometric data as well as of ESR and CRP levels were performed using SPSS software version 20.0 for Macintosh. qRT-PCR data were log-transformed. Statistically significant differences were detected using Student's t tests, paired or unpaired as applicable. Identical conclusions were achieved with standard non-parametric tests. *P*-values less than 0.05 were considered significant in two-tailed testing.

Results {#Sec13}
=======

Clinical characteristics for all participants are given in Table [1](#Tab1){ref-type="table"}. In all of the PMR patients, treatment with prednisolone abolished symptoms within a few days, supporting the PMR diagnosis; at day 15, ESR and CRP levels were markedly reduced in the patients and did no longer differ significantly from values in controls (Table [1](#Tab1){ref-type="table"}). Control subjects had normal ESR and CRP values both before and after treatment (Table [1](#Tab1){ref-type="table"}).

Differential expression of genes in untreated PMR patients vs controls {#Sec14}
----------------------------------------------------------------------

565 transcripts were differentially expressed between patients and controls or before vs after treatment with prednisolone, reflecting either main effect or interaction. Among these transcripts, 165 genes fulfilled at least one of the 2 criteria (Methods) that define the potentially, clinically relevant genes.

Of the 165 genes, expression levels of 78 genes differed between patients and controls before treatment (Fig. [1](#Fig1){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). Among these genes, 41 genes were upregulated in the patients (mean fold difference: 1.4; range: 1.2--1.8), while 37 were downregulated (mean fold difference: 1.5; range: 1.2 − 3.0).Fig. 1Venn-diagram showing 1. the number of genes that differed between untreated patients with polymyalgia rheumatica (PMR) and non-PMR controls (left circle, 34 + 44 genes) and 2. the number of genes that responded to treatment with prednisolone in a given direction in patients with PMR only (right circle, 44 + 87 genes). The overlap of the two circles includes the number of genes which fulfilled both criteria 1 and 2 (44)

In this subset, the biological function (Fig. [2](#Fig2){ref-type="fig"}) of the 78 genes as identified by the DAVID functional annotation clusters (19 clusters in total) included translation/protein biosynthesis (2 clusters, enrichment scores 0.8 and 0.62 \[data not shown), transcription/regulation of transcription (2 clusters, enrichment score 0.69 and 0.4 \[data not shown), nuclear transport and protein transport (enrichment score 0.83), and SH3 domain binding properties (enrichment score 1.15 \[data not shown).Fig. 2Selected clusters of similar biologic functional terms for genes, the expression of which differed between untreated patients with polymyalgia rheumatica (PMR) and non-PMR control subjects. The clusters and the enrichment scores (the geometric means of the EASE scores \[[@CR24]\] of all terms in the cluster) were derived using the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool \[[@CR23]\]. Green squares denote that the gene/term association has been positively reported; black squares denote that the gene/term association has not yet been reported. **a** Cluster with an overall theme of translation/protein biosynthesis and with an enrichment score of 0.8. **b** Cluster with an overall theme of (nuclear) protein transport associated processes and with an enrichment score of 0.83. **c** Cluster with an overall theme of gene expression/transcription regulatory processes and with an enrichment score of 0.69

Genes responding to prednisolone in PMR patients {#Sec15}
------------------------------------------------

Expression of 131 of the total 165 genes responded to prednisolone treatment in patients (Fig. [1](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}); of these genes, two responded significantly to treatment in controls, however in the opposite direction to that seen in patients. Of the 131 genes, the expression of 84 genes was up-regulated upon treatment (mean fold change: 1.7; range: 1.2--4.7); 47 genes were down-regulated (mean fold difference: 1.4; range: 1.2--3.1). In this subset, out of a total of 62 DAVID-identified clusters, the clusters of interesting biological function and high enrichment scores (Fig. [3](#Fig3){ref-type="fig"}) included extracellular matrix organization and cell adhesion (2 highly enriched clusters, enrichment scores 5.58 and 4.11 \[not shown in Fig. [3](#Fig3){ref-type="fig"}\]), cytoskeleton/microtubule organization (2 clusters, enrichment scores 2.38 and 1.62 \[not shown in Fig. [3](#Fig3){ref-type="fig"}\]), and actin filament/cytoskeleton associated processes (1 cluster, enrichment score 1.57).Fig. 3Selected clusters of similar biologic functional terms for genes, the expression of which responded to treatment with prednisolone in a given direction only in patients with polymyalgia rheumatica (PMR); two of the genes in this group of genes (*n* = 131) also responded in non-PMR controls, but in the opposite direction to that seen in patients. The clusters and the enrichment scores (the geometric means of the EASE scores \[[@CR24]\] of all terms in the cluster) were derived using the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool \[[@CR23]\]. Green squares denote that the gene/term association has been positively reported; black squares denote that the gene/term association has not yet been reported. **a** Cluster with an overall theme of extracellular matrix/cell adhesion processes and with an enrichment score of 5.58. **b** Cluster with an overall theme of cytoskeleton/microtubule associated processes and with an enrichment score of 2.38. **c** Cluster with an overall theme of cytoskeleton/actin filament associated processes and with an enrichment score of 1.57

Genes differentially expressed in untreated PMR patients vs controls and also responding to prednisolone in patients {#Sec16}
--------------------------------------------------------------------------------------------------------------------

Among all 165 differentially expressed genes were 44 genes, the expression levels of which differed between untreated patients and controls and which in patients only also responded to prednisolone treatment in a given direction (Fig. [1](#Fig1){ref-type="fig"} and Table [4](#Tab4){ref-type="table"}). Of these 44 genes, the expression levels of 28 genes were higher in untreated patients than in untreated controls (mean fold difference: 1.4; range: 1.2--1.8); the expression levels of 16 genes were lower (mean fold difference: 1.4; range: 1.2--2.0). Upon prednisolone treatment, the expression levels of 27 were down-regulated in patients (mean fold change: 1.4; range: 1.2--3.1), whereas 17 genes were up-regulated (mean fold change: 1.5; range: 1.2--2.7). None of the 44 genes responded significantly to prednisolone treatment in control subjects.

In this subset, out of a total of 8 DAVID-identified clusters, the clusters with the highest enrichment scores (Fig. [4](#Fig4){ref-type="fig"}) comprised genes with transcription regulation (2 clusters, enrichment scores 1.59 and 1.17 \[data not shown) and protein translation/biosynthesis (2 clusters, enrichment score 0.63 and 0.59 \[data not shown) properties.Fig. 4Selected clusters of similar biologic functional terms for genes, the expression of which differed between patients with polymyalgia rheumatica (PMR) and non-PMR control subjects before prednisolone treatment and which also responded to treatment with prednisolone in a given direction only in PMR patients. The clusters and the enrichment scores (the geometric means of the EASE scores \[[@CR24]\] of all terms in the cluster) were derived using the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool \[[@CR23]\]. Green squares denote that the gene/term association has been positively reported; *black* squares denote that the gene/term association has not yet been reported. **a** Cluster with an overall theme of regulation of transcription and with an enrichment score of 1.59. **b** Cluster with an overall theme of translation/protein biosynthesis and with an enrichment score of 0.63

qRT-PCR {#Sec17}
-------

To validate the levels found using microarrays, the expression of some of the genes were measured using qRT-PCR (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, and Fig. [5](#Fig5){ref-type="fig"}).

Nine genes that fulfilled criterion 1 or criterion 2 according to microarray analysis were examined with qRT-PCR (Table [5](#Tab5){ref-type="table"} and Fig. [5b](#Fig5){ref-type="fig"}); 8 of the 9 genes were always regulated in the same direction as found using microarrays. However, for the comparison of patients and controls before treatment (criterion 1), the expression fold differences of 5 genes (COL5A1, MARK4, MTFP1, PRSS23, and TRFC), which were statistically significant in the microarray analysis, did not reach significance using qRT-PCR (*p* \> 0.05). For the treated vs untreated patients comparison (criterion 2), the fold changes for NPM1, PRSS23 and TUBD1 were significant in the microarray but not in the qRT-PCR, whereas the fold change for MARK4 was significant only in qRT-PCR analysis. The fold changes for COL5A1 and TRFC were not statistically significant (*p* \> 0.05) in the microarray nor in the qRT-PCR analysis.

Moreover, the expression levels of 5 genes (Table [5](#Tab5){ref-type="table"}) of potential interest in PMR that did not differ in the microarray analysis were measured using qRT-PCR. Expression levels of IL-6 (Fig. [5a](#Fig5){ref-type="fig"}), which did not differ in the microarray experiments (FD and FC \< 1.1), markedly differed both between untreated patients and controls (FD 4.54, *p* \< 0.05) and between patients before and after treatment (FC ---3.25, *p* \< 0.05) using qRT-PCR (Table [5](#Tab5){ref-type="table"}). The remaining four genes were found to differ neither between untreated patients and controls nor between patients before and after treatment with either method.Fig. 5Muscle (**a**) interleukin 6 (IL-6) and (**b**) brain-derived neurotrophic growth factor (BDNF) mRNA levels normalized to the mRNA levels of the gene encoding ribosomal protein, large P0 (RPLP0; arbitrary units), in patients with polymyalgia rheumatica (PMR, *n* = 9) and non-PMR control subjects (*n* = 9) before and after treatment with prednisolone (20 mg/day) for 14 days. Values are relative to untreated controls (=1.0) and shown on a logarithmic scale. Data are geometric mean and errors bars SEM

Discussion {#Sec18}
==========

In the present study, the gene expression in skeletal muscle was measured for the first time in patients with PMR and in non-PMR, matched controls subjects before and after brief, symptom-relieving prednisolone treatment using DNA microarrays. Microarray findings were supplemented by testing of the expression levels of selected genes with qRT-PCR, which was also used to accurately measure expression levels of genes of particular interest. In all subjects, biopsies were obtained from the trapezius muscle. Before treatment, patients had marked clinical symptoms, including trapezius myalgia and tenderness, as well as elevated ESR and levels of CRP; upon treatment, paraclinical parameters had normalized and clinical symptoms had disappeared.

Subjects were studied in 2008; thus, we were not able to use the most recent PMR criteria, which were published in 2012 \[[@CR17]\]. However, the latter criteria are still provisional and awaiting further validation, and, in the most recent reviews of PMR, the Chuang criteria are mentioned on par with the newer provisional criteria \[[@CR2], [@CR3], [@CR8], [@CR17]\]. The two criteria sets are very similar; however, the fact that the demand for a high ESR is stricter in the Chuang criteria implies that the patients in the present study would also be accepted with the new criteria.

A total of 565 genes were differentially expressed across all groups. In general, when measured by microarray, fold differences and fold changes in expression were modest, ranging from 1.2 (cut-off value) to 1.4 for most genes. Despite the relatively modest differences in gene expression levels, gene function analysis indicated that even these small differences may have a pathophysiological and phenotypic impact in PMR. A few genes were regulated more markedly, with fold differences and changes in the range of 2 to 4. In the microarray measurements, none of the genes that usually are associated with PMR \[[@CR12]\], for example genes encoding proteins involved in inflammation, e.g. IL-6, were differentially expressed in symptom-yielding muscle tissue. However, using the more sensitive qRT-PCR technique, the expression of the IL6 gene showed marked differences between groups, being up-regulated in untreated patients and down-regulated after prednisolone treatment (Fig. [5](#Fig5){ref-type="fig"}). This finding is in line with a previous microdialysis study that indicated a local production of IL-6 in symptom-yielding muscles in patients with PMR, and normalization with prednisolone treatment \[[@CR5]\]. Furthermore, several studies \[[@CR1], [@CR4], [@CR5], [@CR25]\] have found that plasma IL-6 is highly elevated in PMR. In line with a key role in the pathophysiology of the disease, IL-6 blockade has recently in an open-label study been shown to be an effective treatment for newly diagnosed PMR \[[@CR26]\].

Genes differentially expressed in untreated PMR patients vs controls {#Sec19}
--------------------------------------------------------------------

The applied study design allowed for 3 important comparisons. Firstly, by comparing expressions levels in untreated patients and control subjects, 78 genes of possible central importance for the phenotype of PMR were identified.

Although the enrichment scores, which are proportional to the extent to which the cluster is represented in the gene set (here 78 genes), were modest within this subset of genes, functional clustering analysis identified several clusters of genes, many of which were associated with protein translation and biosynthesis. Other identified clusters included regulation of transcription, cellular and nuclear protein transport, and rearrangement of the cytoskeleton; the latter process was also represented in a gene cluster that involved SH-3-domain-binding properties, which are associated with cytoskeletal elements and signaling proteins.

The identification of clusters associated with protein translation, biosynthesis and transport may suggest that PMR is associated with abnormal protein metabolism in muscle. It might be speculated that inflammation and immobilization, which induce negative protein balance in many chronic diseases, accounted for these findings. However, in the protein translation and biosynthesis clusters, more genes were up-regulated rather than down-regulated in patients versus controls in the present cohort. Furthermore, indicating a minor role of inactivity in the present study, the number of genes in muscle influenced by PMR was small compared to findings in response to inactivity per se \[[@CR27]\].

Another finding that may possibly contribute to the muscle complaints, primarily the muscle stiffness, experienced by PMR patients \[[@CR28]\] is that proteins involved in organizing the cytoskeleton, including tubulin delta 1 (TUBD1; similar findings with microarrays and with qRT-PCR) and microtubule affinity-regulating kinase 4 (MARK4; similar differences in microarray and qRT-PCR, but only significant in the former), were up-regulated in patients before prednisolone treatment (Tables [2](#Tab2){ref-type="table"} and [5](#Tab5){ref-type="table"}) \[[@CR28]\].

Another interesting gene in this subset was the gene encoding brain-derived neurotrophic growth factor (BDNF). This neurotrophic growth factor was markedly upregulated in patients before treatment as determined by both microarray and qRT-PCR (Tables [2](#Tab2){ref-type="table"} and [5](#Tab5){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}). While BDNF traditionally is associated with diseases such as Alzheimer's and mood disorders \[[@CR29]\], studies have shown that BDNF is also expressed in satellite cells surrounding skeletal muscle cells, and, based on studies in rats, a role for BDNF in maintaining the satellite cell population has been suggested \[[@CR30]\]. We have previously shown that PMR is associated with high intramuscular levels of proinflammatory cytokines \[[@CR5]\], and it might be speculated that in untreated PMR, BDNF is upregulated to counter the muscle damage resulting from the inflammatory processes as well as the muscle degeneration resulting from the reduced physical activity level of PMR patients.

Finally, the transferrin receptor/CD71 (TFRC) gene was down-regulated 3 fold in patients before treatment. The transferrin receptor protein is involved in the transport of iron into cells, it is required for erythrocyte development, and it is associated with diseases such as iron deficiency, anemia, and chronic disease in general. It has been suggested that low levels of soluble transferrin receptors reflect adaptation to iron deficiency and/or inhibition of iron resorption \[[@CR31]\]. It is conceivable that in this group of patients, TFRC is down-regulated due to the chronic inflammatory disease burden associated with PMR. While intramyocellular iron deficiency may ensue, it is not likely that the muscular down regulation of TFRC was secondary to systemic iron deficiency. This is so because none of the subjects exhibited anemia. Other studies have identified that PMR is associated with antibodies against ferritin \[[@CR32], [@CR33]\]. Taken together, this suggests that iron metabolism and the function of proteins that rely on iron-binding may be influenced in PMR.

Genes responding to prednisolone in PMR patients {#Sec20}
------------------------------------------------

The phenotype of PMR in this and other studies \[[@CR1], [@CR5], [@CR15], [@CR34]\] profoundly responds to treatment with glucocorticoids, indicating that important information about the pathophysiology of the disease can be achieved by studying the gene expression before and after prednisolone treatment. Moreover, if studying only untreated subjects, it is conceivable that, due to sampling errors, including unrecognized impacts of e.g. diurnal gene expression variations between patients and controls, discovery of all genes relevant to the pathophysiology of PMR would not be achieved. For these reasons, comparison of expression levels before and after symptom eliminating prednisolone treatment in patients was also used for the identification of genes with importance for PMR. The number of genes that responded to treatment in a given direction only in patients was 131. Indicating that these genes were, in fact, involved in the pathophysiology of PMR, of the 131 mentioned genes that responded to treatment in patients, only 2 also responded in controls subjects, and they did so in the direction opposite to that seen in the patients. Genes responding in the same direction to prednisolone in both patients and controls were not emphasized, because it is likely that the response reflected a general effect of glucocorticoids of no importance for the pathophysiology of PMR.

The functional clusters in this subset of genes included genes involved in the organization of the cytoskeleton and genes relevant for the extracellular matrix. In this context, it is of note that both TUBD1 and MARK4 were down-regulated by prednisolone, the fold changes being significant in microarray and qRT-PCR, respectively (Table [5](#Tab5){ref-type="table"}). The fact that such genes respond to prednisolone treatment in patients with PMR is in line with the hypothesis that muscle stiffness may be due to abnormal expression of cytoskeleton-related genes. Correspondingly, clinical remission, including abolishment of muscle stiffness, happened in parallel with or due to normalization of expression of such genes.

Genes differentially expressed in untreated PMR patients vs controls and also responding to prednisolone in patients {#Sec21}
--------------------------------------------------------------------------------------------------------------------

The strongest evidence in favor of a pathogenic role of a given gene would be that its expression differed between untreated patients and controls, and, furthermore, changed with prednisolone treatment in the former. The number of such genes was 44 in the present cohort. Strongly indicating that these genes do in fact play a role in PMR, the response to prednisolone of all but one of the 44 genes counteracted the difference in gene expression between untreated patients and controls. In this group of genes, the predominant biological functions appeared to be regulation of transcription as well as protein translation/biosynthesis.

The finding that the expression of some genes differed between untreated patients and controls while not responding to prednisolone treatment in patients may indicate that clinical remission may be achieved even though the underlying disease mechanisms are not completely resolved or that not all differences in gene expression may be of importance for clinical symptoms. As a limitation of the present study, it should be noted, however, that while all patients achieved clinical remission during the relatively brief 14-day treatment period, some genes might respond to long-term treatment only. Conversely, it is also interesting to note that in the untreated patients, some genes, the expression of which did not differ from that of controls, were, nevertheless, selectively influenced by prednisolone. It may be that in the patients the processes regulated by these genes were impaired by other, non-genetic factors that possibly also resulted in increased sensitivity to prednisolone. If so, the condition would be ameliorated by a prednisolone-induced effect on these genes.

Conclusions {#Sec22}
===========

This study is the first to demonstrate changes in the gene expression in skeletal muscle in PMR. The study has identified a number of genes that may play a role in the pathophysiology of PMR. Moreover, we show that the expression of the IL6 gene is upregulated in muscle in PMR, a finding that adds to the substantial body of evidence that this cytokine is central to the disease. Follow-up studies are needed to elucidate the exact pathophysiological relevance of the identified genes; however, it appears that many of the genes are involved in the regulation of protein biosynthesis, which may suggest that abnormal protein metabolism is a disease mechanism in PMR. Effects of prednisolone on genes involved in the organization of the cytoskeleton and the intracellular matrix in PMR patients may contribute to the amelioration, seen in response to treatment, of the muscle stiffness.
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